Ginkgo Bioworks Partners with Inductive Bio and Tangible Scientific for AI-Driven Drug Discovery

August 21, 2025
Ginkgo Bioworks has announced a strategic partnership with Inductive Bio and Tangible Scientific to deploy AI-driven lab-in-the-loop workflows across the biopharma industry, as stated in a press release.

Ginkgo Bioworks has announced a strategic partnership with Inductive Bio and Tangible Scientific to deploy AI-driven lab-in-the-loop workflows across the biopharma industry, announced in a press release. This collaboration aims to make AI-driven drug discovery more accessible by integrating high-throughput experimental workflows, streamlined compound management, and predictive chemistry AI models into a cohesive service.

The partnership leverages Ginkgo Datapoints' rapid ADME profiling, Inductive Bio's model-driven chemistry design platform, and Tangible Scientific's API-enabled compound management platform. This integration is designed to streamline the drug discovery process, reducing synthesis cycles and turnaround times while lowering overall costs.

By aligning design, experimentation, and data delivery into a single connected process, the partnership aims to enhance early-stage drug development efficiency. The services are now available for pharmaceutical and biotech teams seeking to improve ADMET optimization and reduce iteration times.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

08/21
Artera Achieves FedRAMP High 'In Process' Status for Federal Agencies
08/21
LookDeep Health Introduces Aimee: AI Assistant for Hospitals
08/21
Elix Provides AI Drug Discovery Platform to KYORIN Pharmaceutical
08/20
TNO Launches Motion Comfort Institute for Automated Vehicles
08/20
Convoke Secures $8.6M to Develop AI Operating System for Biopharma

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like